This article is more than 5 years old. Information may no longer be current.

Sutureless valve for surgical aortic valve replacement receives FDA approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LivaNova PLC announced that the FDA has approved its sutureless heart valve for use in surgical aortic valve replacement.

The valve (Perceval, LivaNova PLC) is made from bovine pericardium and has a self-anchoring frame that allows a surgeon to replace a diseased aortic valve without suturing the replacement valve into place, according to a company press release. It is indicated for replacement of diseased, damaged or malfunctioning aortic valves, either native or prosthetic.

In clinical studies, implantation procedures involving the sutureless valve has led to significant reduction in surgical procedural time compared with procedures involving sutured valves, with aortic cross-clamp times often decreased by more than 50%, for patients needing isolated or complex aortic valve replacement, according to the release.

Recently, an expert consensus panel issued recommendations on the use of sutureless and rapid deployment valves.